Key result
LMWH overcomes key pharmacokinetic limitations of unfractionated heparin in thromboembolic disease.
Why the study?
Unfractionated heparin has limitations that low-molecular-weight heparins aim to overcome for thromboembolic indications.
No takes yet. Share an insight, caveat, or question.
This review discusses the advantages of low-molecular-weight heparins over unfractionated heparin for treating venous thrombosis, pulmonary embolism, and unstable angina.
Jack Hirsh (1998) conducted a review in Venous thrombosis, pulmonary embolism, and unstable angina. Low-molecular-weight heparins (LMWHs) vs. Unfractionated heparin (UFH) was evaluated. This review discusses the mechanisms by which low-molecular-weight heparins overcome the limitations of unfractionated heparin in treating thromboembolic conditions.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: